	US 12,083,148 B2
	IL13Ra2-binding chimeric antigen receptors
Daniel Abate-Daga, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Appl. No. 16/487,367
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
PCT Filed Feb. 22, 2018, PCT No. PCT/US2018/019147 § 371(c)(1), (2) Date Aug. 20, 2019, PCT Pub. No. WO2018/156711, PCT Pub. Date Aug. 30, 2018.
Claims priority of provisional application 62/462,054, filed on Feb. 22, 2017.
Prior Publication US 2020/0061114 A1, Feb. 27, 2020
Int. Cl. A61K 35/17 (2015.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C07K 14/7155 (2013.01); C07K 16/2866 (2013.01); C12N 5/0636 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)]

14 Claims

1. A chimeric antigen receptor (CAR) polypeptide, comprising an IL13Ra2 antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region; wherein the IL13Ra2 antigen binding domain is single chain variable fragment that specifically binds IL13Ra2 comprising a variable heavy (VH) domain as set forth in SEQ ID NO: 2 and a variable light (VL) domain as set forth in SEQ ID NO: 4.